The FDA has determined that human pregnancy data for Ebglyss® remain insufficient. By enrolling U.S. and Canadian participants, this study will help generate the evidence needed to inform future treatment decisions. PRESS RELEASE San Diego, CA — Pregnant women with moderate-to-severe eczema and their healthcare providers face a difficult evidence gap: how to make treatment decisions when human pregnancy data for newer therapies remain limited.MotherToBaby has launched a new observational …

